Annovis Bio (FRA:07X) Preferred Dividends: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:07X Annovis Bio Inc FRA:07X
38 GF Score
Price €1.51
! 1 Warning Sign
View Full Analysis

What is Annovis Bio Preferred Dividends?

Annovis Bio FRA:07X +0.13% 38 Preferred Dividends is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:07X with a GF Score™ of 38/100. The stock has 1 warning sign investors should review.

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Annovis Bio's preferred dividends for the three months ended in Mar. 2026 was €0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Annovis Bio  (FRA:07X) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio Preferred Dividends Historical Data

* Premium members only.

The historical data trend for Annovis Bio's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio Preferred Dividends Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Preferred Dividends
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Annovis Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:07X
38GF Score
Annovis Bio Inc FRA:07X
Preferred Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annovis Bio Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Frequently Asked Questions Learn more about Preferred Dividends →
What does a Preferred Dividends of €0.00 Mil mean?
Annovis Bio (FRA:07X) has a Preferred Dividends of €0.00 Mil as of Mar. 2026. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Annovis Bio and its competitors.
Is Annovis Bio's Preferred Dividends too high?
Annovis Bio's current Preferred Dividends is €0.00 Mil. Overall, Annovis Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's Preferred Dividends compare to IBIO and ENLV?
Annovis Bio's Preferred Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Dividends for a Biotechnology company?
A good Preferred Dividends depends on the Biotechnology industry context. However, Preferred Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Dividends mean?
A high Preferred Dividends can signal that a stock is expensive relative to its fundamentals. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Annovis Bio and its competitors. Annovis Bio's current Preferred Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current Preferred Dividends of €0.00 Mil. The current Preferred Dividends is €0.00 Mil. Annovis Bio's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Dividends calculated?
Preferred Dividends is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current Preferred Dividends is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
38GF Score

Get the complete analysis for FRA:07X

Preferred Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price